Rituximab in Treating Patients With Mantle Cell LymphomaResearch Question:
How does rituximab after stem cell transplant work compared with rituximab alone in
treating patients with in minimal residual disease-negative mantle cell lymphoma in
first complete remission?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This randomized phase III trial studies rituximab after stem cell transplant and to
see how well it works compared with rituximab alone in treating patients with in minimal
residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal
antibodies, such as rituximab, may interfere with the ability of cancer cells to grow
and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer
cells that are in the body and helps make room in the patient's bone marrow for new
blood-forming cells (stem cells) to grow. After treatment, stem cells are collected
from the patient's blood and stored. More chemotherapy is then given to prepare the
bone marrow for the stem cell transplant. The stem cells are then returned to the
patient to replace the blood-forming cells that were destroyed by the chemotherapy.
Giving rituximab with or without stem cell transplant may work better in treating
patients with mantle cell lymphoma.
Study Reference #: CLYM17103-
Lead Researcher (Principal Investigator)
Lead Researcher: Paul Barr
Study Contact InformationStudy Coordinator: Delaney Dretto
Phone: (585) 275-5825
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search